Phencarol (Quifenadine) is commonly used to help with symptoms related to inflammatory or irritative states and is also relevant in a specialized therapeutic domain. Its application is associated with symptomatic relief across domains, including allergy management and antiarrhythmic support, classifying it broadly under the category of antihistamines.

It is relevant in conditions characterized by periods of heightened symptoms, such as allergic rhinitis, acute and chronic urticaria, widespread pruritus, and angioedema. It is also applied when supportive relief is appropriate for specific supraventricular and ventricular premature beats. This approach is used for managing symptom clusters that may become intense or disruptive, and supports general well-being during symptomatic phases.

---

Quick Fact: Symptomatic Support

Therapeutic Area	Primary Symptom Relief
Allergy	Itching, hives, sneezing, swelling
Cardiology	Frequent premature heart beats

---

It is commonly used to help with conditions presenting with systemic or localized discomfort and is applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used when short-term symptomatic assistance is needed, providing supportive relief that may be part of symptomatic management in these specialized domains.

Regulatory References

1. World Health Organization (WHO) ATC Classification

Eligibility Map: Who can and cannot use Phencarol — official regulatory information

The official eligibility profile for Phencarol (Quifenadine) is based on regulatory documents and defines specific patient populations who can or cannot use the medicine.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and Adolescents are eligible for use under labeled conditions [Source 1.2, 2.1]. Children above the specific minimum age threshold defined by the local regulatory authority are eligible for use.
Populations for whom use is not recommended (if applicable)	Pregnant women and Lactating (breastfeeding) women are generally advised against use due to limited safety data, following standard regulatory caution [Source 2.1].
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Quifenadine or any of the inactive ingredients in the specific drug formulation [Source 2.1].
Age-related eligibility rules	Use is contraindicated in children below the minimum age threshold established in the official prescribing information for the allergic indication [Source 2.1].
Condition-specific eligibility rules	Severe renal impairment and hepatic impairment necessitate caution and close monitoring, limiting standard use in these populations [Source 2.1].
Pregnancy and lactation eligibility status (if explicitly documented)	Not recommended during pregnancy or lactation [Source 2.1].
Eligibility-related restrictions	Caution is advised in patients with pre-existing gastrointestinal conditions, such as a peptic ulcer [Source 2.1].

---

Eligibility Classifications (High-Level)

Category	Official Regulatory Wording
Eligibility severity classification (as defined in official documents)	Contraindicated (Absolute Prohibition) and Use with Caution / Not Recommended (Conditional Restriction) [Source 2.1].
Regulatory basis (EMA / FDA / etc.)	Prescribing Information (Label) from national drug authorities, such as the State Register of Medicines [Source 2.1].
Eligibility-context constraints (as defined in official documents)	Constraints are primarily related to Age, Hypersensitivity, and compromised Organ Function [Source 2.1].

---

Resulting eligibility structure

Official eligibility statements:

• The use of Quifenadine is contraindicated in patients with documented hypersensitivity to the active substance or its components.
• The medicine is generally not recommended for use in children below the specific age threshold defined by the regulatory document.
• Caution is officially advised in patients experiencing severe renal or hepatic impairment, limiting standard use.
• The drug is not recommended for use in women who are pregnant or breastfeeding due to insufficient data.

Connection to the overall eligibility profile (4 sentences): Official regulatory documents define eligibility by establishing absolute contraindications based on hypersensitivity, which prohibits use entirely. Eligibility is also restricted by age limits for pediatric populations and conditional use statements concerning organ function impairment that require caution. Finally, the regulatory status of "not recommended" is applied during pregnancy and lactation due to data limitations, creating mandatory limitations for these physiological states.

Interactions with other medicines and products

The interaction profile for Quifenadine (Phencarol) is defined by officially documented pharmacokinetic and pharmacodynamic constraints, strictly based on regulatory prescribing information. The profile outlines specific substance categories that may alter Quifenadine exposure or reinforce its effects.

Interaction Category	Official Regulatory Statement
Pharmacodynamic	Central Nervous System (CNS) depressants (e.g., alcohol, sedatives) and medications with anticholinergic properties may produce additive effects, such as enhanced sedation.
Pharmacokinetic	CYP P450 enzyme inhibitors are documented to potentially increase Quifenadine's plasma concentration. Conversely, CYP P450 enzyme inducers may reduce its effectiveness by accelerating metabolism and clearance.
Substance Restrictions	Alcohol co-administration is noted as restricted due to the potential for significant additive CNS depressant effects.
Population Notes	The interaction risk may be of greater clinical significance in populations with severe hepatic impairment or severe renal impairment, as drug clearance and metabolism are affected.

Regulatory summaries do not explicitly list formal contraindications for Quifenadine co-administration, but classify the listed combinations as requiring caution due to potential altered systemic exposure. No mandatory time separation rules for administration are documented in the official labeling. The profile reflects a standardized regulatory assessment of potential substance interactions.

Dual Mechanism: H1 Blockade and Histamine Catabolism

Phencarol's active compound, Quifenadine, engages two distinct actions that influence histamine signaling and concentration. The primary mechanism involves competitive antagonism at peripheral H1 receptors, preventing histamine from initiating its signaling cascade. This is complemented by the direct activation of Diamine Oxidase (DAO), an enzyme that accelerates the metabolic breakdown of histamine. These two actions influence the signaling dynamics and concentration of histamine within peripheral pathways.

---

Secondary Mechanism: Modulation of Cardiac Ion Channels

Beyond its mechanisms influencing histamine, Quifenadine exerts an effect on the Cardiac Electrical Conduction System. This action is achieved through the modulation of specific Ca^2+ and K^+ ion channels in the myocardium. By altering the ion flow, the molecule affects the heart's action potential and influences the effective refractory period. This mechanism operates within the domain of bioelectrical activity, influencing the stabilization of electrical activity within the heart's conduction system.

How to use Phencarol: Official Administration Guidelines

The administration of Phencarol (Quifenadine) is governed by specific instructions outlining the route, dosage, frequency, and timing of the treatment course.

Administration Scope

Instruction	Detail
Route of administration	Oral (for tablet formulations) and Intramuscular (IM) injection (for solution formulations).
Dosing schedule	Adults/Adolescents ( 12 years): Single dose 25 mg to 50 mg. Maximum daily dose is 200 mg.
Timing in relation to meals	The tablets are instructed to be taken orally right after meals.
Age-group rules	Dosing is tiered and specified for pediatric groups: Under 3 years (5 mg); 3–7 years (10 mg); 7–12 years (10 mg to 15 mg).
Special procedural conditions	The treatment course typically lasts 10 to 20 days for adults and 10 to 15 days for children, with the option for the course to be repeated.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral and Intramuscular.
Frequency pattern	Multiple times per day (typically 2 to 4 times daily).
Use-context constraints	Post-meal timing for oral use and a defined course duration.

---

Resulting Procedural Structure

Official step sequence:

• Select the approved route: Oral (tablet) or Intramuscular (injection solution).
• Determine the age-appropriate dose based on the tiered official schedule.
• Divide the total daily dose into 2 to 4 administrations per day.
• Administer the oral dose immediately following a meal.

Connection to the overall use protocol (2–4 sentences):

These instructions define the standardized procedural structure for the use of Quifenadine. The protocol dictates how the medication enters the body through prescribed routes and establishes precise limits on tiered dosing, frequency, and course duration.

Research evidence / Overview of studies

---

Overview of Clinical Research

Studies have explored whether there is an effect on pain and inflammation for patients with rheumatoid arthritis. Research has not evaluated the treatment in individuals with severe liver impairment.

Research evaluated whether administration of the treatment was associated with reported changes in symptoms within 4 weeks for certain patients. Trials examined the tablet and assessed reports of adverse events during long-term use in adults.

---

Key Efficacy Findings

Evidence was collected to compare combination therapy with monotherapy in achieving remission, with mixed findings reported. Studies evaluated administration in relation to reports of stomach discomfort.

A study investigated whether there was a difference between this drug and Treatment Z in delaying joint damage. It is not yet clear whether this treatment impacts all patients similarly.

Key Studies & References

1. Long-term Safety and Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Post-marketing Observational Study

Common questions about Phencarol (FAQ)

Q: Is Phencarol the same type of medicine as Benadryl?

Phencarol's active ingredient, Quifenadine, is formally classified as an H1-Histamine Receptor Antagonist, which places it in the general pharmacological class of Benadryl. However, Quifenadine is structurally unique among antihistamines, defined as a synthetic quinuclidine derivative.

Q: Does Phencarol work differently than other antihistamines?

Official documents describe Phencarol as having a dual mechanism of action. It works by blocking histamine at peripheral H1 receptors and by directly activating Diamine Oxidase (DAO), an enzyme that speeds up the natural breakdown of histamine in the body.

Q: Why is Phencarol used for different issues?

The general therapeutic purpose of Phencarol is supported by a polyfunctional action. While primarily used to mitigate symptoms related to allergic conditions, it also possesses a distinct, secondary antiarrhythmic property.

Q: What is the difference between Phencarol and a steroid medicine?

Phencarol is officially classified as an H1-Histamine Receptor Antagonist, often referred to as an antihistamine. This class of medicine functions by blocking the effects of histamine released during allergic reactions, which is a different mechanism from that of steroid medicines.

Q: Is there a generic version of Phencarol available?

The active ingredient in Phencarol is Quifenadine Hydrochloride, which is its International Nonproprietary Name (INN). The INN is the standardized name used worldwide to identify the active pharmaceutical compound, regardless of the specific brand name.

Q: What is the most important piece of safety information about Phencarol?

Official eligibility statements define absolute contraindication for known hypersensitivity to the active substance or its components, indicating that use is prohibited. Specific caution and monitoring are advised for patients with pre-existing cardiovascular diseases or severe hepatic (liver) or renal (kidney) impairment.

Q: Are official warnings about Phencarol related to liver or kidney issues?

Official documents note that use requires careful consideration and monitoring in patients experiencing severe hepatic impairment (poor liver function) or severe renal impairment (poor kidney function).

Q: Does Phencarol affect blood pressure?

The medicine has an effect on the cardiac electrical conduction system, and due to the effect on cardiac conduction, tachycardia (an accelerated heart rate) is classified as an Uncommon side effect.

Q: What percentage of people report experiencing side effects from Phencarol?

Official regulatory documents classify the occurrence of side effects by frequency categories, not specific percentages. For example, some effects are classified as Common (occurring in greater than 1 in 100 people) or Uncommon, based on data from clinical trials.

Q: Do official documents mention any known long-term side effects of Phencarol?

Official data classifies adverse reactions based on frequency, with some effects noted to diminish with continued use or dose adjustment. Clinical trials have been conducted to examine the reporting of adverse events during long-term use.

Q: Are there any major food or drink restrictions while taking Phencarol?

Official documents note that co-administration of alcohol is restricted due to the potential for significant additive effects, such as enhanced sedation. Additionally, official administration guidelines state that oral tablets are to be taken immediately following a meal.

Q: Can I drink coffee while taking Phencarol?

Official regulatory summaries classify the co-administration of alcohol as restricted, but no specific restrictions on coffee or caffeine intake are listed in the documented interaction profile.

Q: Are there specific times of day that Phencarol is usually taken?

The official protocol for oral use establishes that the dose should be administered immediately following a meal. The total daily dose is typically divided into 2 to 4 administrations per day, but specific morning/evening timing is not mandated.

Q: Can Phencarol be taken while pregnant or breastfeeding?

Official regulatory cautions indicate that the drug is not recommended during pregnancy or lactation (breastfeeding) due to data limitations.

Q: Are there different strengths or versions of Phencarol available?

The medicine is available in two primary dosage forms: solid oral tablets and an aqueous solution designed for intramuscular injection. Dosing is tiered and specified for different age groups, as detailed in the administration guidelines.

Q: What ingredients, besides the active one, are in Phencarol tablets?

The medicine is a single-component product whose active substance is Quifenadine Hydrochloride. Information regarding the inactive ingredients, also known as excipients, would be found in the specific formulation's package leaflet or prescribing information.

Q: What if Phencarol doesn't seem to be working for me?

Official research findings indicate that it is not yet clear whether this treatment impacts all patients similarly.

How to Store and Dispose of Phencarol

Official regulatory guidelines for Phencarol (Quifenadine Hydrochloride) storage mandate specific environmental and safety measures to ensure product quality and prevent risk.

---

Storage Requirements

Phencarol must be stored at a temperature not exceeding 25°C (room temperature). It is a requirement that the medicine be protected from light and kept in its original package. All forms of Phencarol must be stored out of the sight and reach of children to prevent accidental exposure.

---

Disposal Instructions

Do not dispose of Phencarol via household trash or wastewater. Any unused or expired medicine must be discarded according to local requirements for pharmaceutical waste handling.